This interview says many deadly diseases already have treatments, but people need to use them proactively. Guest Alex Karnal argues GLP-1 drugs (like Novo Nordisk and Eli Lilly's) first proved people will pay to manage health—oral versions hit $150/month and sales soared. But he's more excited about PCSK9 inhibitors (cholesterol-lowering drugs), calling them 'the closest thing to a free lunch' with fewer side effects and bigger long-term potential than GLP-1s. He also notes AI drug-discovery firms (like Lila Sciences) can find drug candidates in a month, but only if their data is reliable.
Alex Karnal (co-founder of Braidwell) introduced the "health stack" framework on the program, arguing that most fatal diseases can already be addressed with existing drugs. The core thesis is: GLP-1 drugs are the first commercial proof that people are willing to proactively manage their health, while PCSK9 inhibitors, despite lower attention, may be an even more important drug class. He warned that most published literature used to train AI companies is irreproducible, but believes biology is moving toward deterministic scientific superintelligence. Key conclusions include: defensive health strategies are divided into five layers, GLP-1 represents a turning point, PCSK9 inhibitors are seen as the "closest thing to a free lunch" in medicine, and automated laboratories will drive a revolution in drug discovery.
Alex Karnal argues that drugs are already available for most diseases that cause human death, and the key lies in shifting from "passive treatment" to "active defense." He proposes the concept of a "health stack," comprising five core defense layers: lipid optimization, cardiometabolic health, neurocognitive health, inflammatory health, and blood pressure. Each layer has approved drugs, but the public has not fully utilized them.
> Karnal's assessment: "Most diseases that will take our lives already have drugs that can address them. The gap is not in needing more drugs, but in how to direct these drugs toward the impact they can have."
Karnal believes that GLP-1 drugs represent the "first commercial proof" that people are willing to take proactive action for long-term health. Three major findings in 2025 support this judgment: consumers prioritize "tolerability" over maximum weight loss, direct-to-consumer channels (such as Lilly Direct) contribute over half of new users, and price elasticity is enormous.
> Karnal's assessment: "People are not looking for the most powerful 'rocket launcher'; they are looking for something that allows them to lose weight, stabilize, and stick with it long-term. Tolerability is more important than maximum weight loss."
Karnal believes that PCSK9 inhibitors are the "closest thing to a free lunch" in pharmaceuticals, and in the long term, their market may be larger than that of GLP-1s, though current adoption is slow due to "invisible benefits." By lowering LDL cholesterol by 50%, this drug reduces the future risk of heart attack or stroke by over 20% in patients with a history of such events, and by approximately 25% in high-risk populations.
> Karnal asserts: "PCSK9 inhibitors are very close to a free lunch. GLP-1s have real toxicity, but for PCSK9—we have human genetic evidence that people who don't produce this protein live longer and healthier lives."
Karnal believes that the greatest value of AI in drug discovery lies in breaking the constraints of "the human brain and hands," but this requires high-quality, reproducible data. He warns that most published literature is "irreproducible," so AI companies relying solely on public data will fall into a "garbage in, garbage out" predicament.
> Karnal's assessment: "We are on a deterministic curve toward scientific superintelligence in biology. AI means we are no longer limited by brain and hands—we can generate all possible hypotheses and run experiments at an unprecedented scale."
| Position | Guest Stance | Key Data |
|---|---|---|
| Eli Lilly | Bullish (GLP-1 leader) | Oral Wegovy monthly cost $150, weekly new prescriptions increased from 200k to 300k; risk of progression from prediabetes to diabetes reduced by 94% |
| Novo Nordisk | Bullish (GLP-1 pioneer) | Heart attack/stroke risk reduced >20% (independent of weight loss) |
| Amgen | Neutral (under watch) | Developing GLP-1 dosed monthly/quarterly |
| Pfizer | Neutral (under watch) | Acquired a monthly GLP-1 candidate |
| Biogen | Neutral (Alzheimer's field) | Cognitive decline slowed by ~30% in late-stage patients |
| Exact Sciences | Bullish (colorectal cancer screening) | Stool test has high sensitivity, but completion rate limited by sample mailing |
| Guardant Health | Bullish (colorectal cancer screening) | Blood test "is accelerating," addressing Exact Sciences' completion rate issue |
| Capstan | Bullish (next-generation CAR-T) | No cell extraction needed; intravenous injection attacks cancer cells in vivo; tumor shrinkage of 100% achieved in >70% of patients |
| Lila Sciences | Bullish (AI drug discovery) | From model to molecule within one month |
| Anabla | Bullish (AI drug discovery) | Same as above |
| Neko | Neutral (skin imaging) | No specific data provided |
| Prenuvo | Neutral (whole-body imaging) | No specific data provided; Karnal personally has not adopted it, concerned about false positive rate |
1. The “Health Stack” Five-Layer Defense (Karnal): Lipid optimization, cardiometabolic health, neurocognition, inflammation, and blood pressure—each layer has approved drugs that are underutilized by the public. Support: For individuals aged 40–80, the 30%–50% risk of cardiovascular events can be reduced to below 10% with existing medications.
2. GLP-1 Is the “First Commercial Proof” (Karnal): People are willing to take proactive action for long-term health. Support: When the monthly cost of oral Wegovy was $150, weekly new prescriptions surged from 200,000 to 300,000; compounded GLP-1 accounts for 15%–20% of the market, demonstrating significant price elasticity.
3. PCSK9 Inhibitors Are the “Closest Thing to a Free Lunch in Drugs” (Karnal): A 15-year follow-up of individuals with genetic deficiencies showed an 88% reduction in cardiovascular risk, with no known serious side effects. Support: Animal models indicate that LDL does not drop to zero; the long-term patient base and revenue potential for this drug should exceed that of GLP-1.
4. The Benefits of GLP-1 Are Independent of Weight Loss (Karnal): Novo Nordisk data show a >20% reduction in heart attack/stroke risk, unrelated to weight loss. Support: Protective effects against addiction (alcohol, drugs, gambling) are emerging in the data, which cannot be achieved through dieting alone.
5. The Key Bottleneck in AI Drug Discovery Is Data Quality (Karnal): Most published literature is not reproducible; AI companies relying solely on public data will fall into a “garbage in, garbage out” trap. Support: Successful AI companies must have proprietary methods for generating “scientific tokens,” which form a competitive moat.
6. Automated Labs Will Achieve “Scientific Superintelligence” (Karnal): Within 5–10 years, AI agents combined with robotics will run experiments 24/7, freeing scientists from pipetting. Support: Screening that traditionally took years has been compressed to one month; this path follows a “deterministic scaling law.”
7. The “Sensitivity vs. Specificity” Trade-off in Cancer Screening (Karnal): Multi-cancer early detection is advancing, but the false positive rate remains a major risk. Support: Colonoscopy is still the gold standard; blood tests (e.g., Guardant) are accelerating, but Karnal personally avoids whole-body imaging (e.g., Prenuvo) due to concerns over false positive interference.
8. “Citizen Pharmacology” Runs Parallel to FDA Reform (Karnal): Self-experimentation on platforms like Reddit reflects a trend of “people not wanting to wait,” while FDA Commissioner Marty Makary is pushing for accelerated reviews and reduced animal testing. Support: The FDA is introducing AI systems to review thousands of pages of filings; Karnal believes the entire system is “pursuing faster, more efficient” processes.